Rigel Pharmaceuticals RIGL GAVRETO (pralsetinib) — Acquisition-related liabilities

Similar metrics at other companies

ZETAAcquisition Related Liabilities Non Current

$22.3M-5.7%

APPSAcquisition purchase price liabilities

$436K-74.3%

GLOOAcquisition Related Liabilities Noncurrent

$649K—

IVTAcquisition, Accounts Payable, Acquired Lease Intangibles, and Other Liabilities

$8.74M+87.1%

PCORDeferred asset acquisition payment included in other current and non-current liabilities and accrued expenses at period end

$300K-85.3%

CYTKLiabilities Related To Revenue Participation Right Purchase Agreement Net

$539.11M+13.2%

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's gavreto (pralsetinib) — acquisition-related liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's GAVRETO (pralsetinib) — acquisition-related liabilities?: Rigel Pharmaceuticals (RIGL) reported GAVRETO (pralsetinib) — acquisition-related liabilities of $5M in Q1 2026.
What does GAVRETO (pralsetinib) — acquisition-related liabilities mean?: This represents the balance sheet liabilities recognized as a result of the GAVRETO acquisition, such as contingent consideration or deferred payments. It reflects the ongoing financial obligations the company carries related to the asset's purchase. Investors monitor this to understand the company's leverage and future cash flow commitments.